Please login to the form below

Not currently logged in
Email:
Password:

Celyad appoints Dr David Gilham as R&D vice president

He will resign from the company’s advisory board to fulfill his new role

Celyad Dr David GilhamBelgian biopharmaceutical company Celyad has selected Dr David Gilham to be its new vice president of research and development.

Currently a member of Celyad's immuno-oncology scientific advisory board, Dr Gilham will resign from his post in August to fulfill his new role from 1 September.

Dr Gilham brings extensive experience in the field of CAR-T cells, with his research activity focused on engineering T-cells for cancer therapies and pre-clinical study development. 

Before joining Celyad Dr Gilham was a Reader in the Institute of Cancer Sciences at the University of Manchester, and led the Manchester Cancer Research Centre's clinical and experimental immunotherapy group.

Dr Gilham said: “I am truly excited to be joining Celyad at such an important time in its history.

“Engineering immune system T-cells to attack and eradicate cancer is at the leading edge of cancer research and I look forward to advancing Celyad's unique portfolio of cell therapy candidates in the clinic.”

16th June 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics